The U.S. healthcare system, including patients, employers and taxpayers, saved $408 billion in 2022 by using FDA-approved generic and biosimilar drugs, per the AAM's report.
Lisdexamfetamine dimesylate is indicated for the treatment of ADHD in patients 6 years and above and for adults with moderate to severe Binge Eating Disorder.
Lisdexamfetamine is indicated for the treatment of ADHD in adults and pediatric patients aged 6 years old and older and moderate to severe binge eating disorder in adults.
Lisdexamfetamine Dimesylate capsules are a federally controlled substance used to treat Attention-Deficit/Hyperactivity Disorder and other indications.
